Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
| Status: | Withdrawn |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 1998 |
| End Date: | January 2000 |
Rituximab Anti-CD20 Monoclonal Antibody and Dexamethasone in the Treatment of Relapsed Indolent Lymphoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells. Combining the monoclonal
antibody rituximab with dexamethasone may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab and dexamethasone in
treating patients with recurrent or refractory indolent non-Hodgkin's lymphoma.
tumor-killing substances to them without harming normal cells. Combining the monoclonal
antibody rituximab with dexamethasone may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab and dexamethasone in
treating patients with recurrent or refractory indolent non-Hodgkin's lymphoma.
OBJECTIVES: I. Determine the toxic effects of rituximab and dexamethasone in patients with
recurrent or refractory indolent non-Hodgkin's lymphoma. II. Determine the objective tumor
response rate and duration of response at 2 months after initiation of therapy, and the
percentage of patients with progressive disease. III. Determine the maximum response,
duration of response, and progression free interval for patients who have not progressed
after 4 weeks of therapy. IV. Determine the failure-free and overall survival of these
patients on this regimen. V. Compare the response rate and survival rates to results for
similar patients (historical and concurrent) who have received 4 weeks of rituximab without
dexamethasone, and patients who did not receive maintenance rituximab.
OUTLINE: Patients receive dexamethasone IV followed by rituximab IV on days 1, 8, 15, and 22
for one course. Two months after initiating treatment, patients are evaluated for disease
progression. Patients with stable or responding disease may receive monthly dexamethasone
and rituximab therapy for up to 10 additional months. Patients are followed every 3 months
for 2 years, then every 6 months for years 3-4, and then yearly for up to 5 years.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
recurrent or refractory indolent non-Hodgkin's lymphoma. II. Determine the objective tumor
response rate and duration of response at 2 months after initiation of therapy, and the
percentage of patients with progressive disease. III. Determine the maximum response,
duration of response, and progression free interval for patients who have not progressed
after 4 weeks of therapy. IV. Determine the failure-free and overall survival of these
patients on this regimen. V. Compare the response rate and survival rates to results for
similar patients (historical and concurrent) who have received 4 weeks of rituximab without
dexamethasone, and patients who did not receive maintenance rituximab.
OUTLINE: Patients receive dexamethasone IV followed by rituximab IV on days 1, 8, 15, and 22
for one course. Two months after initiating treatment, patients are evaluated for disease
progression. Patients with stable or responding disease may receive monthly dexamethasone
and rituximab therapy for up to 10 additional months. Patients are followed every 3 months
for 2 years, then every 6 months for years 3-4, and then yearly for up to 5 years.
PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Histologically proven stage III or IV, recurrent or refractory,
indolent B cell non-Hodgkin's lymphoma of the following types: Working Group Formulation A
(small cell lymphocytic) Working Group Formulation B, C, and D (follicular) Must have
relapsed after prior chemotherapy At least 1 lymph node or visceral lesion at least 2 cm
in diameter
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy:
Not specified Hematopoietic: Lymphocyte count less than 5,000/mm3 Hepatic: Not specified
Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective
contraception No active infection HIV negative No hepatitis B or C No concurrent life
threatening condition
PRIOR CONCURRENT THERAPY: Biologic therapy: No prior monoclonal antibody therapy for
lymphoma (e.g., rituximab) Chemotherapy: See Disease Characteristics Endocrine therapy: No
other concurrent corticosteroids and/or epinephrine (unless anaphylactic shock)
Radiotherapy: Not specified Surgery: Not specified
We found this trial at
3
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials